Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Managing Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years With a Treat and Extend (T&E) Regimen of 2 mg Intravitreal Aflibercept - a Randomized, Open-label, Active-controlled, Parallel-group Phase IV/IIIb Study (ARIES)

Trial Profile

Managing Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years With a Treat and Extend (T&E) Regimen of 2 mg Intravitreal Aflibercept - a Randomized, Open-label, Active-controlled, Parallel-group Phase IV/IIIb Study (ARIES)

Status: Completed
Phase of Trial: Phase III/IV

Latest Information Update: 18 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Polypoidal choroidal vasculopathy; Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms ARIES
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 12 Jul 2022 Results of post-hoc analysis assessing the requirement for intravitreal aflibercept treatment intervals of <8 weeks in patients with neovascular age-related macular degeneration, and to assess vision and anatomic outcomes in such patients who require more intensive treatment, published in the Ophthalmology and Therapy.
    • 18 Mar 2022 Results of post-hoc analysis assessing the relationship between the presence of intraretinal fluid (IRF) and subretinal fluid (SRF), both at baseline and throughout treatment, and best-corrected visual acuity (BCVA) in patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal aflibercept, published in the Ophthalmology and Therapy.
    • 23 Jan 2022 Results of a post hoc analysis describes outcomes in patients with treatment-naive nAMD receiving treat and extend intravitreal aflibercept for 104 weeks, who were identified as meeting criteria for an early hypothetical switch published in the Ophthalmology and Therapy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top